Psoriasis: Targets and Therapy (Sep 2024)
Secukinumab Causing Medication-Related Osteonecrosis of the Jaw, in a Patient Diagnosed with Psoriasis and Rheumatoid Arthritis
Abstract
Lukas Hauer,1 Omid Moztarzadeh,1,2 Nasimeh Baghalipour,1 Jiri Gencur1 1Department of Stomatology, University Hospital Pilsen, Faculty of Medicine in Pilsen, Charles University, Pilsen, 32300, Czech Republic; 2Department of Anatomy, Faculty of Medicine in Pilsen, Charles University, Pilsen, 32300, Czech RepublicCorrespondence: Omid Moztarzadeh, Department of Anatomy, Faculty of Medicine in Pilsen, Charles University, alej Svobody 1655/76, Pilsen, 32300, Czech Republic, Tel +420 377 593 306, Email [email protected]; [email protected]: The use of antiangiogenic and antiresorptive medications, particularly in patients with cancer or osteoporosis, can lead to osteonecrosis of the jaw following tooth extraction, trauma or arising spontaneously- A condition known as medication-related osteonecrosis of the jaw (MRONJ). In this article, we present a unique case of MRONJ in a patient with no history of antiresorptive or antiangiogenic drug use, who was instead taking the anti-interleukin 17-A (Secukinumab) medication for severe psoriasis. This association has not been previously reported in the literature.Keywords: plaque psoriasis, anti-interleukin 17-A, immunomodulator, interleukins inhibitors, MRONJ
